PGM1 deficiency is linked to sarcomeric and mitochondrial dysfunction in patient-derived iPSC-cardiomyocytes

Read full text Summarise with VIRAT
Authors: Silvia Radenkovic, Graeme J. Preston, Rohit Budhraja, Irena Josephina Johanna Muffels, Anna N. Ligezka, Nathan P. Staff, Ron F. Hrstka, Bijina Balakrishnan, Rameen Shah, Sanne Verberkmoes, Ibrahim Shammas, Inez Bosnyák
+6 more Kyle M. Stiers, Kent Lai, Lesa J. Beamer, Akhilesh Pandey, Eva Morava, Tamás Kozicz
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background PGM1-congenital disorder of glycosylation (PGM1-CDG) is frequently associated with cardiomyopathy. Although galactose therapy corrects glycosylation defects, cardiac dysfunction typically persists, suggesting a glycosylation-independent mechanism. Recent evidence of mitochondrial abnormalities in PGM1-deficient human and murine heart, together with the association of PGM1 with the Z-disk protein LDB3 (ZASP/Cypher), suggests a critical role for PGM1 in cardiomyocyte structural and energetic homeostasis. We hypothesized that PGM1-related cardiomyopathy arises from a glycosylation-independent disruption of Z-disk–mitochondrial coupling driven by loss of PGM1–LDB3 interactions, resulting in mitochondrial energy failure and impaired contractile function. Methods Induced pluripotent stem cell–derived cardiomyocytes (iCMs) were generated from PGM1-deficient patient fibroblasts. Multielectrode array (MEA) recordings, untargeted (glyco)proteomics, and pathway analysis were performed to assess functional and molecular changes. Key findings were validated using tracer metabolomics and mitochondrial respiration assays. Results PGM1-deficient iCMs exhibited reduced beating frequency, impaired contractility, and prolonged contraction kinetics. Proteomic analyses revealed depletion of Z-disk components, including LDB3. AlphaFold3 structural modeling predicted a direct interaction between PGM1 and LDB3, implicating PGM1 in Z-disk integrity, which was confirmed in vitro. In addition, mitochondrial proteins were severely depleted, prompting us to investigate mitochondrial function. Functional validation confirmed extensive metabolic rewiring, energy depletion, and severely impaired mitochondrial respiration. Finally, the in silico drug repurposing identified possible therapeutic options that could target PGM1-deficient cardiomyopathy. Conclusion Our data suggests PGM1 is key regulator of cardiomyocyte function, linking sarcomeric Z-disk integrity with mitochondrial metabolism. These mechanistic insights offer a foundation for developing targeted therapies for PGM1-CDG and potentially other cardiomyopathies involving Z-disk dysfunction. Graphical Abstract

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Glycosylation and Glycoproteins Research Metabolism and Genetic Disorders

Publication details

Journal / source
Figshare
Publication date
21 February 2026
Language
EN